Drug Trial Radar · NCT05446870
Pembrolizumab With Chemotherapy and MK-4830 for Treating Participants With Ovarian Cancer (MK-4830-002)
Last checked: Nov 19, 2026Latest source record: Oct 1, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
160
Actual
Start
Jul 25, 2022
Primary completion
Dec 20, 2023
Study completion Oct 16, 2024
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Jul 7, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective is to evaluate in participants with high-grade serous ovarian cancer (HGSOC), whether the reduction from baseline in circulating tumor deoxyribonucleic acid (ctDNA) at Cycle 3 (ΔctDNA) is larger in participants receiving MK-4830 + pembrolizumab in combination with standard of care (SOC) therapy than in those receiving pembrolizumab + SOC therapy.
Conditions
- High-grade Serous Ovarian Carcinoma
- Ovarian Carcinoma
Interventions
PembrolizumabBiological
200 mg by IV infusion on Day 1 of each 21-day cycle
PaclitaxelDrug
175 mg/m\^2 by IV infusion on Day 1 of each 21-day cycle
CarboplatinDrug
AUC 5 to 6 by IV infusion on Day 1 of each 21-day cycle
AvastinBiological
According to local practice and at the choice of the investigator.
MK-4830Biological
800 mg by IV infusion on Day 1 of each 21-day cycle
DocetaxelDrug
75 mg/m\^2 by IV infusion on Day 1 of each 21-day cycle
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Circulating Tumor Deoxyribonucleic Acid (ctDNA)Time frame: Baseline and Week 7
Locations
45 sites in 11 countries. Site status is shown where the registry gives one.
University of Colorado Anschutz Medical Campus-Cancer Clinical Trials Office ( Site 0108)
Aurora, Colorado
Mayo Clinic in Florida ( Site 0101)
Jacksonville, Florida
Miami Cancer Institute at Baptist Health, Inc. ( Site 0110)
Miami, Florida
Northwestern Memorial Hospital ( Site 0104)
Chicago, Illinois
Washington University ( Site 0113)
St Louis, Missouri
Rutgers Cancer Institute of New Jersey ( Site 0114)
New Brunswick, New Jersey
Roswell Park Cancer Institute ( Site 0106)
Buffalo, New York
Perlmutter Cancer Center at NYU Langone Hospital - Long Island ( Site 0116)
Mineola, New York
Laura and Isaac Perlmutter Cancer Center at NYU Langone ( Site 0107)
New York, New York
Memorial Sloan Kettering Cancer Center ( Site 0102)
New York, New York
Sanford Cancer Center-Gynecologic Oncology ( Site 0115)
Sioux Falls, South Dakota
Fred Hutchinson Cancer Center ( Site 0100)
Seattle, Washington
Antwerp University Hospital-Oncology ( Site 1301)
Edegem, Antwerpen, Belgium
AZ Maria Middelares-IKG ( Site 1302)
Ghent, Oost-Vlaanderen, Belgium
UZ Leuven ( Site 1300)
Leuven, Vlaams-Brabant, Belgium
Centre Hospitalier de l'Université de Montréal ( Site 0300)
Montreal, Quebec, Canada
McGill University Health Centre ( Site 0301)
Montreal, Quebec, Canada
James Lind Centro de Investigación del Cáncer ( Site 0903)
Temuco, Araucania, Chile
FALP ( Site 0905)
Santiago, Region M. de Santiago, Chile
Pontificia Universidad Catolica de Chile-Centro del Cáncer ( Site 0900)
Santiago, Region M. de Santiago, Chile
ONCOCENTRO APYS-ACEREY ( Site 0904)
Viña del Mar, Valparaiso, Chile
Rambam Health Care Campus-Gyneco-oncology unit ( Site 0602)
Haifa, Israel
Shaare Zedek Medical Center ( Site 0601)
Jerusalem, Israel
Sheba Medical Center-ONCOLOGY ( Site 0600)
Ramat Gan, Israel
Istituto Europeo di Oncologia IRCCS-Divisione di Ginecologia Oncologica ( Site 0501)
Milan, Italy
Istituto Nazionale Tumori IRCCS Fondazione Pascale-S.C. Oncologia Sperimentale Uro-Genitale ( Site 0
Naples, Campania, Italy
Fondazione Policlinico Universitario Agostino Gemelli-Ginecologia Oncologica ( Site 0502)
Rome, Lazio, Italy
Fondazione IRCCS Istituto Nazionale dei Tumori-Struttura Complessa Chirurgia Ginecologica ( Site 050
Milan, Lombardy, Italy
Uniwersytecki Szpital Kliniczny w Poznaniu-Oddzial Ginekologii Onkologicznej ( Site 0709)
Poznan, Greater Poland Voivodeship, Poland
Mazowiecki Szpital Wojewódzki w Siedlcach-Siedleckie Centrum Onkologii ( Site 0701)
Siedlce, Masovian Voivodeship, Poland
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Ginekologii Onkologicznej ( Sit
Warsaw, Masovian Voivodeship, Poland
Uniwersyteckie Centrum Kliniczne-Klinika Ginekologii, Ginekologii Onkologicznej i Endokrynologii Gi
Gdansk, Pomeranian Voivodeship, Poland
Swietokrzyskie Centrum Onkologii, Samodzielny Publiczny Zaklad Opieki Zdrowotnej ( Site 0708)
Kielce, Świętokrzyskie Voivodeship, Poland
National Cancer Centre Singapore ( Site 1501)
Singapore, Central Singapore, Singapore
National University Hospital ( Site 1502)
Singapore, South West, Singapore
Seoul National University Hospital ( Site 0801)
Seoul, South Korea
Severance Hospital, Yonsei University Health System-Gynecologic cancer center ( Site 0800)
Seoul, South Korea
Hospital Universitari Vall d'Hebron-Departamento de Oncologia- VHIO ( Site 1101)
Barcelona, Spain
Instituto Catalan de Oncologia - Hospital Duran i Reynals-Medical Oncology ( Site 1103)
Hospitalet, Barcelona, Spain
Hospital Universitario 12 de Octubre-Medical Oncology ( Site 1104)
Madrid, Madrid, Comunidad de, Spain
Showing 40 of 45 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.